- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00424203
Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
Multicenter Pilot Clinical Study of Adjuvant Chemotherapy for Subjects Over 70 Years: Impact on the Independence and Quality of Life of the Administration of Anthracycline-Based Chemotherapy in Adjuvant Setting for Patients Presenting With Immediately Operable Breast Cancer, Hormone Receptor Negative (RH-), and Lymph Node Positive (pN+) or pN0 But of Scarff-Bloom-Richardson* Grade III and ≥ 2cm [GERICO]
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying how well giving doxorubicin together with cyclophosphamide works in treating older women with stage I , stage II, or stage III breast cancer that has been removed by surgery.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- Determine the independence of older women with resected stage I, II, or III breast cancer treated with adjuvant doxorubicin hydrochloride and cyclophosphamide.
Secondary
- Determine the impact of this regimen on other aspects of the patient's life, utilizing the Comprehensive Geriatric Assessment, the Mini-Nutritional Assessment, the Folstein Mini-Mental State Exam, the Geriatric Depression Scale, and the Cumulative Illness Rating Scale-Geriatrics.
- Determine the quality of life of patients treated with this regimen.
- Determine the acceptability of this regimen in these patients.
- Determine the toxicity of this regimen, in terms of cardiac issues and anemia, in these patients.
- Determine recurrence-free survival, event-free survival, and overall survival of patients treated with this regimen.
OUTLINE: This is a pilot, nonrandomized, multicenter study.
Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients complete questionnaires at baseline and after completion of chemotherapy. Questionnaires include the Comprehensive Geriatric Assessment, the Mini-Nutritional Assessment (malnutrition), the Folstein Mini-Mental State Exam (cognitive function), the Geriatric Depression Scale (depression), the Cumulative Illness Rating Scale - Geriatrics (comorbidities), and the EORTC Quality of Life Questionnaire Core 30 (quality of life).
After completion of study therapy, patients are followed every 3 months for 4 years.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49036
- Centre Paul Papin
-
Avignon, France, 84082
- Institut Sainte Catherine
-
Bordeaux, France, 33076
- Institut Bergonie
-
Clermont-Ferrand, France, 63011
- Centre Jean Perrin
-
Levallois, France, 92309
- Hopital Perpetuel Secours
-
Lyon, France, 69373
- Centre léon Bérard
-
Marseille, France, 13273
- Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
-
Nantes-Saint Herblain, France, 44805
- Centre Regional Rene Gauducheau
-
Paris, France, 75015
- Hopital Europeen Georges Pompidou
-
Paris, France, 75248
- Institut Curie Hopital
-
Reims, France, 51056
- Institut Jean Godinot
-
Rennes, France, 35042
- Centre Eugène Marquis
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Saint Cloud, France, 92211
- Centre René Huguenin
-
Senlis, France, 60309
- C.H. Senlis
-
Toulouse, France, 31052
- Institut Claudius Regaud
-
Vandoeuvre-les-Nancy, France, 54511
- Centre Alexis Vautrin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed invasive adenocarcinoma of the breast
Stage I, II or III disease
- pN+ or pN0 with grade III disease (tumor size ≥ 2 cm)
- No metastatic disease
Must have undergone prior conservative or radical surgery that included axillary lymph node or sentinel node dissection
- No residual tumor
- Negative margins
Hormone receptor status:
- Estrogen receptor and progesterone receptor negative
PATIENT CHARACTERISTICS:
- Female
- Postmenopausal
- Absolute neutrophil count > 1,500/mm³
- Platelet count > 100,000/mm³
- Hemoglobin > 10 g/dL
- Alkaline phosphatase < 2.5 times upper limit of normal (ULN)
- Bilirubin < 1.25 times ULN
- AST and ALT < 2.5 times ULN
- Creatinine clearance ≥ 40 mL/min
- No contraindication to receiving anthracyclines or alkalizing agents
- FEV normal
Activities of Daily Living (ADL) score ≥ 5
- No decrease of ≥ 1 point within the past 3 months
None of the following at baseline:
- Cognitive deficiency (Folstein Mini-Mental State < 25)
- Severe depression (Geriatric Depression Scale ≥ 20)
- Severe malnutrition (Mini-Nutritional Assessment ≤ 17)
No other serious comorbid condition (Cumulative Illness Rating Scale - Geriatrics grade 3-4), including any of the following:
- Cardiac insufficiency
- Unstable angina
- Myocardiopathy
- Myocardial infarction within the past year
- Uncontrolled hypertension
- Uncontrolled high-risk arrhythmia
- Severe medullary insufficiency
- Neurological or psychological condition that would preclude study consent
- Uncontrolled or active infection
- Severe urinary tract infection
- Preexisting hematuria
- Active ulcer
- Uncontrolled diabetes
- No other cancer within the past 5 years except for basal cell skin cancer or carcinoma in situ of the cervix
- No familial, geographical, social, or psychological condition that would preclude study participation
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 60 days since prior therapeutic surgery
- At least 4 weeks since prior investigational drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Myocet, Endoxan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients maintaining their independence as assessed by Activities of Daily Living (ADL) score on 6 items after the fourth course of chemotherapy
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Impact of adjuvant chemotherapy on ADL score, quality of life, treatment acceptability, toxicity, and survival (recurrence-free, progression-free, and overall survival)
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: E. G. C. Brain, MD, PhD, Institut Curie
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- stage IIIA breast cancer
- stage IIIB breast cancer
- depression
- stage II breast cancer
- stage IIIC breast cancer
- stage IA breast cancer
- stage IB breast cancer
- estrogen receptor-negative breast cancer
- malnutrition
- progesterone receptor-negative breast cancer
- cognitive/functional effects
- psychosocial effects of cancer and its treatment
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Nutrition Disorders
- Depression
- Breast Neoplasms
- Malnutrition
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- CDR0000523419
- FRE-FNCLCC-GERICO-06-0502
- EU-20667
- EUDRACT-2005-000069-20
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
Clinical Trials on cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted